In CVD management, early detection and timely initiation of appropriate treatment are crucial. As a market leader in cardiac biomarkers, Roche is committed to continuing cardiology research to advance early diagnosis and help improve clinical decisions.
NT-proBNP is a well-established Heart Failure (HF) biomarker that can accurately provide objective information to support clinical decision-making from diagnosis to monitoring, to deliver improved care for every HF patient.
NT-proBNP is recognised as the Gold Standard HF biomarker because it is a powerful prognosticator regardless of therapy.7
GDF-15 is the strongest predictor in the ABC bleeding risk score, providing an improved understanding of each patient’s bleeding-risk profile which may help to inform treatment decisions.13
Acute Coronary Syndrome
cTnT-hs is a highly sensitive test that allows for earlier detection of AMI, facilitating faster triaging for earlier initiation of appropriate therapy.8-10
A joint approach with Troponin T detection at the Point-of-Care can help achieve faster triaging of patients with suspected acute myocardial infarction in pre-hospital care and the emergency room.11,12
This page is provided as a contact service and does not replace the advice of a physician. Roche cannot respond to questions about general medical information or questions regarding your personal medical condition. Medications and diagnostics products can not be directly ordered through this website. Please note that we do not respond to form letters or e-mail campaigns.
NT-proBNP: N-terminal prohormone of brain natriuretic peptide; POC: point of care